A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The optimal prioritization of second-line chemotherapy and immune therapy based on
demographic or biomarker data is an area of ongoing investigation. The hypothesis of this
study is that there may be an additive or synergistic antitumor effect of combined
chemotherapy and nivolumab in the second-line treatment of NSCLC as an important concept to
test in a clinical trial. Previously treated NSCLC remains a setting of unmet clinical need
despite recent clinical research progress. Early progression for a subset of NSCLC patients
receiving nivolumab is a specific area of clinical need.